FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Ozkok, Abdullah ^a   Kekik, Cigdem ^a   Karahan, Gonca Emel ^a   Sakaci, Tamer ^b   Ozel, Alper ^b   Unsal, Abdulkadir ^b   Yildiz, Alaattin ^a,c  

^a ISTANBUL UNIVERSITY   (Turkey)

^b SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Coronary artery calcification; Fibroblast growth factor 23; Hemodialysis; Vascular calcification

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHORUS;

ADULT; AGED; ARTICLE; BLOOD VESSEL CALCIFICATION; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY CALCIUM SCORE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PROSPECTIVE STUDY;

BIOLOGICAL MARKERS; CALCINOSIS; CAUSALITY; COMORBIDITY; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TURKEY;

EID: 84886733283     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-241     Document Type: Article

References (27)

1. Vascular calcification in patients with end-stage renal disease. Floege J, Ketteler M, Nephrol Dial Transplant 2004 19 Suppl 5 2259 V66 15284362
2. Coronary artery calcification and coronary flow velocity in haemodialysis patients. Caliskan Y, Demirturk M, Ozkok A, Yelken B, Sakaci T, Oflaz H, Unsal A, Yildiz A, Nephrol Dial Transplant 2010 25 8 2685 2690 10.1093/ndt/gfq113 20190240
3. Serum phosphate levels and mortality risk among people with chronic kidney disease. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL, J Am Soc Nephrol 2005 16 520 528 10.1681/ASN.2004070602 15615819 (Pubitemid 41725150)
4. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nasrallah MM, El-Shehaby AR, Salem MM, Osman NA, El Sheikh E, Sharaf El Din UA, Nephrol Dial Transplant 2010 25 8 2679 2685 10.1093/ndt/gfq089 20176609
5. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. Shimada T, Hasegawa H, Yamazaki Y, et al. J Bone Miner Res 2004 19 429 435 15040831 (Pubitemid 38787398)
6. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Shimada T, Yamazaki Y, Takahashi M, et al. Am J Physiol Renal Physiol 2005 289 1088 F1095 10.1152/ajprenal.00474.2004 15998839 (Pubitemid 41447065)
7. Relationship between circulating FGF23 and total body atherosclerosis in the community. Mirza MA, Hansen T, Johansson L, Ahlstrom H, Larsson A, Lind L, Larsson TE, Nephrol Dial Transplant 2009 24 3125 3131 10.1093/ndt/gfp205 19429932
8. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Mirza MA, Larsson A, Lind L, Larsson TE, Atherosclerosis 2009 205 385 390 10.1016/j.atherosclerosis.2009.01.001 19181315
9. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C, Nephrol Dial Transplant 2009 24 948 955 18852190
10. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, de Filippi C, Wolf M, Circulation 2009 19;119 19 2545 2552
11. Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Srivaths PR, Goldstein SL, Silverstein DM, Krishnamurthy R, Brewer ED, Pediatr Nephrol 2011 26 6 945 951 10.1007/s00467-011-1822-0 21359960
12. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. Gutiérrez OM, Mannstadt M, Isakova T, et al. N Engl J Med 2008 359 584 592 10.1056/NEJMoa0706130 18687639
13. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Jean G, Terrat JC, Vanel T, et al. Nephrol Dial Transplant 2009 24 2792 2796 10.1093/ndt/gfp191 19395730
14. Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients. Ozkok A, Caliskan Y, Sakaci T, Erten G, Karahan G, Ozel A, Unsal A, Yildiz A, Clin J Am Soc Nephrol 2012 7 6 965 973 10.2215/CJN.11191111 22490874
15. Quantification of coronary artery calcium using ultrafast computed tomography. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R, J Am Coll Cardiol 1990 15 827 832 10.1016/0735-1097(90)90282-T 2407762 (Pubitemid 20101575)
16. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group, Kidney Int 2002 62 1 245 252 10.1046/j.1523-1755.2002.00434.x 12081584 (Pubitemid 34754068)
17. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ, N Engl J Med 1998 339 27 1972 1978 10.1056/ NEJM199812313392703 9869668 (Pubitemid 29024129)
18. Coronary and aortic calcifications in patients new to dialysis. Spiegel DM, Raggi P, Mehta R, Lindberg JS, Chonchol M, Ehrlich J, James G, Chertow GM, Block GA, Hemodial Int 2004 8 3 265 272 10.1111/j.1492-7535.2004.01104.x 19379426 (Pubitemid 41024997)
19. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M, J Am Soc Nephrol 2005 16 2205 2215 10.1681/ASN.2005010052 15917335 (Pubitemid 41716454)
20. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Scialla JJ, Lau WL, Reilly MP, Isakova T, Yang HY, Crouthamel MH, et al. Kidney Int 2013 83 6 1159 1168 10.1038/ki.2013.3 23389416
21. FGF-23 and the progression of coronary arterial calcification in patients new to dialysis. Khan AM, Chirinos JA, Litt H, Yang W, Rosas SE, Clin J Am Soc Nephrol 2012 7 12 2017 2022 10.2215/CJN.02160212 22997345
22. FGF-23 induces left ventricular hypertrophy. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. J Clin Invest 2011 121 11 4393 4408 10.1172/JCI46122 21985788
23. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. Isakova T, Gutierrez O, Shah A, Castaldo L, Holmes J, Lee H, Wolf M, J Am Soc Nephrol 2008 19 615 623 10.1681/ASN.2007060673 18216315 (Pubitemid 351355405)
24. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T, Shuto E, Nashiki K, Arai H, Yamamoto H, Takeda E, Kidney Int 2006 70 2141 2147 17063170 (Pubitemid 44871378)
25. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. Liu S, Tang W, Zhou J, et al. J Am Soc Nephrol 2006 17 1305 1315 10.1681/ASN.2005111185 16597685 (Pubitemid 43673410)
26. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. Ito N, Fukumoto S, Takeuchi Y, Takeda S, Suzuki H, Yamashita T, Fujita T, J Bone Miner Metab 2007 25 419 422 10.1007/s00774-007- 0779-3 17968495 (Pubitemid 350043699)
27. The essentials of calcium, magnesium and phosphate metabolism: part I. Baker SB, Worthley LIG, Physiol Crit Care Resusc 2002 4 301 306